论文部分内容阅读
目的探讨锌制剂辅助治疗婴幼儿轮状病毒性肠炎的临床意义。方法 64例婴幼儿轮状病毒性肠炎患儿,按照随机数字表法分为对照组和观察组,各32例。对照组采用常规治疗方法 ,观察组在对照组治疗方法基础上加用锌制剂。比较两组治疗效果。结果治疗前两组血清白细胞介素-2(IL-2)、白细胞介素-10(IL-10)比较差异无统计学意义(P>0.05)。两组患儿治疗10 d后IL-2较治疗前升高,而IL-10水平降低,且观察组血清IL-2高于对照组,IL-10低于对照组,差异均有统计学意义(P<0.05)。观察组痊愈22例、有效8例、无效2例,治疗总有效率为93.75%;对照组痊愈14例、有效10例、无效8例,治疗总有效率为75.00%;观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。随访3个月,观察组复发2例,少于对照组的11例,差异有统计学意义(P<0.05)。结论婴幼儿轮状病毒性肠炎的治疗中加入锌制剂辅助治疗可改善患者免疫调节功能,从而提高临床效果,降低复发风险。
Objective To investigate the clinical significance of zinc preparations in the treatment of infantile rotavirus enteritis. Methods Sixty-four infants with rotavirus enteritis were divided into control group and observation group according to the random number table method, with 32 cases in each group. Control group using conventional treatment methods, the observation group in the control group based on the treatment with zinc preparations. Compare the treatment effect of two groups. Results There was no significant difference in serum interleukin-2 (IL-2) and interleukin-10 (IL-10) between the two groups before treatment (P> 0.05). The levels of IL-2 in the two groups of children after treatment for 10 days were higher than those before treatment, while the level of IL-10 was decreased. The serum IL-2 in the observation group was higher than that in the control group, IL-10 was lower than the control group, the differences were statistically significant (P <0.05). In the observation group, 22 cases were cured, 8 cases were effective and 2 cases were ineffective. The total effective rate was 93.75%. In the control group, 14 cases were cured, 10 cases were effective and 8 cases were ineffective. The total effective rate was 75.00% Higher than the control group, the difference was statistically significant (P <0.05). Follow-up 3 months, the observation group recurred in 2 cases, less than the control group, 11 cases, the difference was statistically significant (P <0.05). Conclusion The adjuvant treatment with zinc preparation in the treatment of infantile rotavirus enteritis can improve the immunomodulatory function in patients, thereby improving the clinical effect and reducing the risk of relapse.